Medtronic to Acquire SPR Therapeutics for $650M to Boost Pain Treatment Offerings

• The acquisition gives Medtronic access to SPR's SPRINT system, a 60-day therapy offering pain relief without permanent implants
• SPR Therapeutics specializes in non-opioid, non-surgical, minimally invasive pain management solutions
• The deal is valued at $650 million in cash and expected to close in the first half of fiscal 2027 (beginning April 25, 2026), pending regulatory approval

Summary

Deal Overview:

Medtronic Plc announced plans to acquire privately held SPR Therapeutics for approximately $650 million in cash on May 20. The acquisition aims to expand Medtronic's chronic pain treatment portfolio with less invasive options.

Key Asset:

The deal provides Medtronic access to SPR's SPRINT system, a 60-day therapy that delivers pain relief without requiring permanent implantation. SPR Therapeutics specializes in non-opioid, non-surgical, and minimally invasive pain management solutions.

Strategic Rationale:

Medtronic stated the acquisition will enable the company to reach more patients seeking less invasive pain relief alternatives. This aligns with growing demand for non-opioid pain management options amid ongoing concerns about opioid addiction and surgical complications.

Timeline:

The transaction is expected to close in the first half of Medtronic's fiscal year 2027, which began on April 25, 2026, pending regulatory approvals.

Market Implications:

This acquisition represents Medtronic's continued expansion in the pain management sector, positioning the medical device maker to capture market share in the growing non-opioid pain therapy segment. The deal reflects broader healthcare industry trends favoring temporary, minimally invasive treatments over permanent implants and surgical interventions. For investors, this strategic move could strengthen Medtronic's competitive position in pain management against rivals while addressing the healthcare system's shift away from opioid-based treatments. The $650 million price tag suggests significant value placed on SPR's innovative platform and its commercial potential.